Martin Sutter
Managing Director, Co-Founder @ Essex Woodlands Healthcare Partners
Palo Alto, United States
Martin Sutter is a Series C investor at Essex Woodlands Healthcare Partners in Palo Alto focused on Health Care and Medical. Marty Sutter is one of the two founding Managing Directors of Essex Woodlands. Educated in chemical engineering and finance, he has more than 30 years of management experience in operations, marketing, finance and venture capital.Mr. Sutter founded and managed The Woodlands Venture Capital Company, a wholly-owned subsidiary of Mitchell Energy& Development Corporation, and The Woodlands Venture Partners, an independent venture capital partnership. During his tenure with both organizations, he founded a number of successful healthcare companies originating from various institutions of the world renowned Texas Medical Center. As a consequence of numerous co-investments with Jim Currie, Mr. Sutter merged his venture practice with Essex Venture Partners, founded by James Currie, to form Essex Woodlands Health Ventures in 1985.Mr. Sutter has been directly involved with more than 30 of Essex Woodlands portfolio investments, and has served on numerous Boards of Directors of public and private companies including portfolio companies ATS Medical (acquired by Medtronic), BioForm Medical (acquired by Merz GmbH), LifeCell (acquired by Kinetic Concepts), St. Francis Medical (acquired by Kyphon [Medtronic]), Confluent Surgical (acquired by Tyco [Covidien]) and Rinat Neurosciences (acquired by Pfizer).Mr. Sutter currently serves on the Board of Directors of Abiomed, QSpex Technologies and Bioventus. In addition to the portfolio company boards on which he serves today, Mr. Sutter serves on the Board of Trustees of The Culinary Institute of America and was the past Chairman of The Texas Lyceum.Mr. Sutter holds a Bachelor of Science degree from Louisiana State University and a Master of Business Administration degree from the University of Houston.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Martin Sutter invests in
Stages Martin Sutter invests in
Countries Martin Sutter invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 4 (67%)
- Medical 3 (50%)
- Medical Device 3 (50%)
- Biotechnology 2 (33%)
- Manufacturing 2 (33%)
Stage
- Series C 2 (33%)
- Series D 1 (17%)
- Funding Round 1 (17%)
- Post-IPO Equity 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
MiMedx Group
|
MiMedx Group is a biopharmaceutical company, develops, and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. MiMedx Group’s proprietary processingmethodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications, OrthoFlo, an amniotic fluid-derived allograft for homologous applications, Physio, a bone grafting material comprising 100% bone tissue with no added carrier, and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. It also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue, AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process, and AmnioFill, a cellular tissue matrix allograft that enhances healing. MiMedX Group's products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. It sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group began operation on February 28, 2008. It has its headquarters in Marietta in Georgia. | $100M / Post-IPO Equity / Jul 02, 2020 | |
|
MiMedx Group
|
MiMedx Group is a biopharmaceutical company, develops, and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. MiMedx Group’s proprietary processingmethodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications, OrthoFlo, an amniotic fluid-derived allograft for homologous applications, Physio, a bone grafting material comprising 100% bone tissue with no added carrier, and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. It also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue, AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process, and AmnioFill, a cellular tissue matrix allograft that enhances healing. MiMedX Group's products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. It sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group began operation on February 28, 2008. It has its headquarters in Marietta in Georgia. | $100M / Post-IPO Equity / Jul 02, 2020 | |
BioTissue
|
TissueTech is an innovative technology company that uses products derived from human amniotic and umbilical cord tissues. Its medical technology platform markets innovative amniotic and umbilical cord-based products, thereby enabling physicians to avail of enhanced regenerative healing technology in eye care, wound care, and orthopedics.Tissuetech was founded in 2001 and is headquartered in Miami, Florida. | $82.3M / Series C / Jun 26, 2019 | |
Qspex Technologies
|
QSpex Technologies, Inc. has developed a unique and patented method to produce high quality premium lenses right in your office. It’s simple, cost effective and, above all, the lenses and treatment options provide the high quality you demand for your patients. All lens treatments are pre-applied to the inside surface of each mold and transfer tobecome part of the lens during the polymerization (curing) process. | $12M / Oct 28, 2009 | |
Confluent Surgical
|
Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts. | $23M / Series D / Mar 31, 2005 | |
|
Confluent Surgical
|
Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts. | $20M / Series C / Jun 25, 2002 |
Co-Investors
Essex Woodlands was founded in 1985 with the establishment of Essex Venture Fund I, LP. Since 1985, the Partnership has raised seven additional funds with nearly $2.5 billion under management, making Essex Woodlands one of the world's largest and most established healthcare venture capital firms. The team is comprised of 23 professionals withprincipal offices in Palo Alto, Houston, New York and London. This team brings over 300 years of collective healthcare experience.For over 20 years, the firm has maintained its dedicated focus to diversified healthcare investing—primarily serving as lead investor in the founding or the critical financings of over 100 healthcare companies in pharmaceutical, biotechnology, medical device, services and information technology sectors. In addition to its long-standing commitment to early stage companies, the firm has over a decade of experience as a leading late-stage healthcare investor, which includes mature venture, growth equity and PIPE investment opportunities.
Essex Woodlands Healthcare Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Brooks Andrews
Associate
|
|||
Guido Neels
Managing Director
|
|||
Immanuel Thangaraj
Managing Director
|
|||
|
Martin Sutter
Managing Director, Co-Founder
|
|||
Robert White
Operating Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Martin Sutter invest in?
Martin Sutter invests primarily in Health Care, Medical and Medical Device startups, most often at Series C and Series D stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Martin Sutter?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Martin Sutter last invest?
The most recent investment recorded for Martin Sutter closed in Jul 2020. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
